Daré Bioscience receives $1M NIH funding for HPV treatment May 26, 2026 08:01AM
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer May 26, 2026 08:00AM
Daré Bioscience begins phase 2 trial of HPV infection treatment May 18, 2026 08:01AM
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies May 18, 2026 08:00AM
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update May 14, 2026 04:01PM
View Older Stories

May 12, 2026 08:01AM Daré Bioscience reports interim Phase 3 results for hormone-free contraceptive
May 12, 2026 08:00AM Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
May 7, 2026 08:00AM Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026
Mar 26, 2026 04:01PM Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
Mar 23, 2026 08:00AM On National Viagra Day, Women Finally Claim Their Turn:
Mar 20, 2026 08:00AM Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
Mar 16, 2026 08:02AM Dare Bioscience receives NIH funding extension for preterm birth treatment
Mar 16, 2026 08:00AM Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
Mar 12, 2026 08:00AM Daré Bioscience Participates in Virtual Investor “What This Means” Segment
Feb 23, 2026 08:01AM Dare Bioscience gets FDA clearance for HPV treatment phase 2 trial
Feb 23, 2026 08:00AM Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
Feb 11, 2026 08:00AM Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women
Dec 10, 2025 08:01AM Daré Bioscience launches sildenafil cream for women's arousal
Dec 10, 2025 08:00AM DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facil
Dec 1, 2025 08:03AM Dare Bioscience regains rights to contraceptive drug from Bayer
Dec 1, 2025 08:00AM Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization
Nov 24, 2025 08:01AM Dare Bioscience receives $3.6 million Gates Foundation grant payment
Nov 24, 2025 08:00AM Daré Bioscience Receives $3.6 Million in Additional Grant Funding
Nov 13, 2025 04:01PM Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 11, 2025 08:00AM Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women
Nov 6, 2025 08:00AM Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025
Nov 3, 2025 08:00AM Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment
Oct 6, 2025 08:03AM Dare Bioscience receives $4 million grant installment for drug delivery
Oct 6, 2025 08:00AM Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Bro
Sep 24, 2025 08:00AM Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
Aug 14, 2025 04:01PM Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 7, 2025 08:00AM Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025
Jul 29, 2025 08:00AM Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream
Jul 21, 2025 01:47PM UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar
Jul 21, 2025 08:00AM Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar
Jul 14, 2025 08:03AM Daré Bioscience reports interim Phase 3 results for hormone-free contraceptive
Jul 14, 2025 08:00AM Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
Jul 11, 2025 08:00AM Daré Bioscience receives $6 million grant installment for contraception device
Jul 11, 2025 08:00AM Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application P
Jun 12, 2025 05:00PM Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders
Jun 4, 2025 08:01AM Dare Bioscience (DARE) and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream
Jun 4, 2025 08:00AM Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream
May 13, 2025 04:01PM Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update
May 6, 2025 08:00AM Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025
Apr 23, 2025 08:00AM Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation
Apr 7, 2025 08:00AM Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available v
Mar 31, 2025 04:01PM Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update
Mar 24, 2025 08:00AM Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025
Feb 20, 2025 08:04AM Daré Bioscience (DARE) and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant
Feb 20, 2025 08:00AM Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant
Feb 6, 2025 08:02AM Dare Bioscience (DARE) Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development
Feb 6, 2025 08:00AM Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development
Jan 9, 2025 08:00AM Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 16, 2024 08:04AM Dare Bioscience (DARE) Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder
Dec 16, 2024 08:00AM Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
View Older Stories